Regeneron

What Regeneron does

Regeneron Pharmaceuticals is a public biopharmaceutical company (NASDAQ: REGN), founded in 1988 and headquartered in Tarrytown, New York, that discovers, develops, manufactures, and commercializes medicines for serious diseases. The company markets 15 approved or authorized therapies spanning ophthalmology (Eylea, Eylea HD), immunology and inflammatory disease (Dupixent via Sanofi collaboration), oncology (Libtayo), rare disease, and genetic medicine (Otarmeni, the first FDA-approved gene therapy for genetic hearing loss, received accelerated approval in April 2026). Its pipeline comprises roughly 50 candidates, with 2025 R&D investment of $5.9B and a broad focus that includes hematology, cardiovascular, neuroscience, and infectious disease.

The company's R&D engine is built on its proprietary VelociSuite® technology platform — including VelociGene® for genetic engineering, VelocImmune® for human antibody generation, and Veloci-T, Veloci-N, and related tools — which Regeneron uses internally and licenses to select partners. The Regeneron Genetics Center (RGC) is among the largest human sequencing efforts in industry, with 3M+ exomes sequenced and corresponding deidentified health records, generating data assets that feed target discovery and validation. Manufacturing is conducted in-house across multiple sites in the U.S. and Ireland.

Regeneron monetizes through direct product sales (Libtayo, Eylea franchise, Evkeeza, Inmazeb, etc.), profit-share and royalty arrangements with major partners (Sanofi for Dupixent and other antibodies, Bayer for Eylea outside the U.S., Roche for Ronapreve, Alnylam for cemdisiran), milestone payments, and technology licensing. Q1 2026 revenue was $3.6B (+19% YoY), with Dupixent profit share +42% and Eylea HD +52% YoY in that quarter. The end customer base spans patients, prescribers, payers, and government health systems across more than 100 countries, served via a combination of Regeneron's own specialty commercial infrastructure and partner-led distribution. The 10,000+ employee organization added a dedicated Global Capability Center in Hyderabad (announced May 2026) and a new Office of AI led by a Chief AI Officer (Divya Pathak) and Chief Digital & Technology Officer (Ryan Steinberger), reflecting an effort to scale digital and AI engineering alongside the core scientific enterprise.

Name

Regeneron

Legal name

Regeneron Pharmaceuticals, Inc.

Website

https://regeneron.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Regeneron Pharmaceuticals (NASDAQ: REGN) is a Tarrytown, NY-based biopharmaceutical company that uses its proprietary VelociSuite® antibody and genetics platform to discover, develop, manufacture, and commercialize 15 approved therapies across ophthalmology, immunology, oncology, and rare/genetic disease, serving patients globally via direct sales and major partner collaborations with Sanofi, Bayer, and others.

Ownership category

akta.pro rank

Headquarters

HQ city

Tarrytown

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Biologic product sales (Eylea franchise and other Regeneron-invented medicines): Regeneron commercializes 13 U.S. FDA-approved medicines and 10 EMA-authorized medicines, with 15 approved or authorized Regeneron-invented medicines available in over 100 countries. Q1 2026 reported 19% year-over-year revenue growth to $3.6 billion (driven significantly by Eylea HD growth of 52%, offsetting competitive pressure on the broader Eylea franchise including a 10% decline to $941 million in the prior quarter). Revenue model: one-time product sales of biologic therapies.
2. Collaboration profit-sharing (Sanofi / Dupixent): Regeneron shares profits from the Sanofi collaboration for Dupixent (dupilumab), with Q1 2026 showing 42% growth in Regeneron's share of profits from this collaboration. Dupixent global net sales jumped 31%. This high-margin profit-sharing arrangement is expected to grow in 2H once the development cost repayment balance to Sanofi is fully paid off by mid-year, allowing Regeneron to capture its full share. Revenue model: profit-share / licensing-royalty hybrid.
3. Out-licensing and royalty agreements: Regeneron has executed 50+ new licensing and collaboration agreements over the past five years, including out-licensing of the IL-1 blocker (Arcalyst) to Kiniksa Pharmaceuticals (with Kiniksa reporting $213.4 million in Q1 2026 Arcalyst sales, 56% YoY growth) and global ophthalmology collaborations with Bayer. Includes access to Regeneron technologies & medicines for third-party studies. Revenue model: licensing-royalties.
4. Co-development R&D funding and milestone payments: Strategic research collaborations with multiple partners — Intellia (CRISPR), Alnylam (RNAi, with multiple programs), BioNTech (immuno-oncology combinations), Sonoma Biotherapeutics (Treg cell therapy), Nykode (vaccines), Tessera (gene editing), and Hansoh (olatexopatide/HS-20094 for obesity) — provide upfront, milestone, and R&D funding. Revenue model: collaboration funding and milestones.
5. Government and institutional contracts (Ebola, public health preparedness): Regeneron has received WHO recommendation for its Ebola antibody (maftivimab/MBP134) for investigational use in Bundibugyo outbreak response and has donated up to 500 doses of Ebola treatment to the WHO for exclusive use in low- and lower-middle-income countries. Includes U.S. government and foundation funding (e.g., FNIH Biomarkers Consortium).

Pricing tiers

Go-to-market motion3 records

Distribution channels10 records

Core offering

Regeneron Pharmaceuticals is a fully integrated biopharmaceutical company that invents, develops, manufactures, and commercializes biologic medicines. It commercializes 13 U.S. FDA-approved, 10 EMA-authorized, and 7 PMDA-approved medicines across ophthalmology, immunology, oncology, rare diseases, cardiovascular, and infectious disease, with nearly 50 additional candidates in clinical development. Nearly 100% of product candidates are invented in-house and produced through the company's IOPS biologics manufacturing operations.

Product overview

Regeneron is a fully integrated biopharmaceutical company offering a portfolio of 15 approved/authorized Regeneron-invented medicines (13 FDA-approved) rather than a single software product. The commercial portfolio spans ophthalmology (EYLEA / EYLEA HD, with Bayer), immunology (Dupixent, with Sanofi; Arcalyst/Kevzara), oncology (Libtayo, fianlimab, linvoseltamab, odronextamab), rare diseases (Otarmeni gene therapy for OTOF hearing loss; Lynozyfic/linvoseltamab for AL amyloidosis; Evkeeza for HoFH), cardiovascular (Praluent; REGN7508 Factor XI), infectious disease (REGEN-COV COVID-19 antibodies, Ebola maftivimab/MBP134), and investigational metabolic assets (olateforpatide, garetosmab, trevogrumab). Almost 100% of candidates are invented in-house and powered by the proprietary VelociSuite® antibody-discovery platform (VelociGene®, VelocImmune®) and the Regeneron Genetics Center® (RGC) — a wholly owned subsidiary with >3 million sequenced exomes that drives target discovery using machine learning, AI and large-scale analytics. The Internal Operations & Product Supply (IOPS) organization manufactures these biologics at the Rensselaer, NY and Limerick, Ireland sites, while a global commercial, R&D and — new in 2026 — Hyderabad Global Capability Centre (GCC) supports clinical operations, advanced data science, AI engineering and commercial analytics. Regeneron also operates the Regeneron Science Talent Search and Regeneron ISEF programs, and runs dozens of R&D collaborations (Sanofi, Bayer, Roche, Alnylam, Intellia, BioNTech, Sonoma, Nykode, CytomX, Parabilis, 2seventy bio, Decibel, Checkmate, etc.) that expand its antibody, cell therapy, gene therapy, gene editing and RNAi capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Regeneron Genetics Center (RGC): One of the world's largest genomic databases, focused on human genetics-guided drug discovery with over 3 million sequenced exomes
• Regeneron Cell Medicines
• VelociSuite
• IOPS (Industrial Operations and Product Supply)
• Regeneron Science Talent Search (STS)
• Regeneron International Science and Engineering Fair (ISEF)
• Eylea (aflibercept) / Eylea HD
• Libtayo (cemiplimab)

Products and services

• EYLEA / EYLEA HD (aflibercept)
• Dupixent (dupilumab)
• Libtayo (cemiplimab)
• Otarmeni (lunsotogene parvec-cwha)
• Lynozyfic (linvoseltamab)
• Arcalyst (rilonacept)
• REGEN-COV / Ronapreve (casirivimab and imdevimab)
• Praluent (alirocumab)
• Kevzara (sarilumab)
• Evkeeza (evinacumab)
• Maftivimab / MBP134 (Ebola antibody)
• VelociSuite® Technologies (VelociGene® and VelocImmune®)
• Regeneron Genetics Center® (RGC) Research Services
• Industrial Operations and Product Supply (IOPS) Biologics Manufacturing

Quantifiable outcome

• 15 approved or authorized Regeneron-invented medicines in U.S. or other countries
• +16 more outcomes

Named customers18 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability10 records

Feature7 records

Partnerships

22 partnerships are on record, tiered core, flagship / core and peripheral.

• 2seventy biocoreStrategic or Co-development Partner · 30 January 2024Regeneron acquired full development and commercialization rights to 2seventy bio's cell therapy pipeline. Acquisition included an upfront payment of $5 million and milestone payment for first major market approval. Led to formation of Regeneron Cell Medicines. Transaction expected to close in first half of 2024.
• Decibel Therapeuticsflagship / coreStrategic or Co-development Partner · 9 August 2023Acquisition completed Q3 2023 for approximately $109 million in cash (with potential additional payments if certain clinical milestones are achieved). Brought three gene therapy programs targeting congenital hearing loss in-house, including DB-OTO (now Otarmeni/lunsotogene parvec — the first FDA-approved gene therapy for genetic hearing loss).
• Checkmate PharmaceuticalscoreStrategic or Co-development Partner · 19 April 2022Regeneron acquired Checkmate Pharmaceuticals for approximately $250 million to expand its portfolio of investigational immune activator therapies.
• Sanofiflagship / coreStrategic or Co-development PartnerLong-standing antibody and immunotherapy collaboration. Most prominent component is the Dupixent (dupilumab) co-development and profit-sharing arrangement, which generated 42% growth in Regeneron's profit share in Q1 2026 alongside 31% growth in global Dupixent net sales. Also includes sarilumab (Kevzara) and itepekimab collaboration. Brook Jennings guided global launches of the first three Dupixent indications.
• Bayerflagship / coreStrategic or Co-development PartnerGlobal ophthalmology collaboration partner. Co-promotes the Eylea franchise (Eylea and Eylea HD) outside the U.S. Eylea HD Q1 2026 sales surged 52%, while broader Eylea sales declined 10% to $941M.
• Alnylam Pharmaceuticalsflagship / coreStrategic or Co-development PartnerRNAi therapeutics collaboration covering multiple programs: ALN-APP (Alzheimer's), ALN-APOC3 (dyslipidemia), ALN-CFB (PNH), ALN-CIDEB (MASH), ALN-F1202 (Factor XII), ALN-HTT02 (Huntington's), ALN-PNP (MASLD), ALN-SNCA (Parkinson's), ALN-SOD (SOD1 ALS), ALN-ANG3 (diabetic kidney disease), and cemdisiran (C5 for gMG; FDA Priority Review target action date November 2026). Includes recent expansion of ALN-HSD (rapirosiran) for HSD17B13. Cemdisiran FDA priority review voucher used.
• Intellia Therapeuticsflagship / coreStrategic or Co-development PartnerStrategic R&D collaboration advancing CRISPR/Cas9 in vivo gene editing for genetic diseases. Co-developing nexiguran ziclumeran (NTLA-2001, "nex-z") for transthyretin amyloidosis (ATTR-CM and ATTRv-PN) — Phase 3 enrollment expected to complete in H2 2026. Intellia's lonvo-z (hereditary angioedema) submitted FDA BLA; Intellia also developing Nex-z in partnership with Regeneron.
• BioNTechflagship / coreStrategic or Co-development PartnerSince 2020, Regeneron and BioNTech have advanced a growing collaboration exploring synergistic immuno-oncology treatment combinations for several cancer types. Companies are advancing clinical development of Regeneron's homegrown PD-1 inhibitor in combination with BioNTech's FixVac mRNA vaccine candidate. Most recent agreement offers BioNTech the enhanced ability to pair Regeneron's PD-1 inhibitor broadly across their investigational portfolio.
• Rocheflagship / coreStrategic or Co-development PartnerGlobal manufacturing and distribution collaboration for REGEN-COV (Regeneron's COVID-19 monoclonal antibody cocktail). The collaboration more than tripled manufacturing capacity and ultimately supplied millions of doses globally during the pandemic.
• Kiniksa PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerRegeneron granted Kiniksa an exclusive license to develop and commercialize Regeneron's IL-1 blocker (rilonacept/Arcalyst) — Regeneron's first FDA-approved therapy, originally approved in 2008 — in many countries around the world. Since the 2017 agreement, Kiniksa has led evaluation in IL-1α/IL-1β-mediated diseases. Arcalyst Q1 2026 sales $213.4M (+56% YoY); 2026 forecast $930-945M.
• Sonoma BiotherapeuticscoreStrategic or Co-development PartnerTreg cell therapy research, development and commercial collaboration. One of Regeneron's key cell therapy platform partnerships.
• Nykode TherapeuticscoreStrategic or Co-development PartnerVaccine collaboration. Part of Regeneron's broader exploration of vaccine technologies and combinations with Regeneron pipeline assets.
• CytomX TherapeuticscoreStrategic or Co-development PartnerResearch collaboration initially established in 2022 to develop next-generation conditionally-activated bispecific cancer immunotherapies. Expanded on June 3, 2026 with a $37 million target selection payment for two additional programs and option for six more future targets, bringing total potential milestone value to $4 billion. Combines CytomX's Probody® platform with Regeneron's Veloci-Bi technology.
• Parabilis Medicines (formerly FogPharma)flagship / coreStrategic or Co-development PartnerStrategic research collaboration announced May 18, 2026 to discover and develop multiple therapeutic candidates based on Parabilis' Helicon™ peptide platform, focused on Antibody-Helicon Conjugates (AHCs). Parabilis receives $125 million ($50M cash + $75M equity) with potential milestone payments of up to ~$2.2 billion plus tiered royalties. Regeneron also participated in Parabilis's $770.5M IPO via $75M private placement (June 2026). Total relationship value up to $2.3 billion.
• Tessera TherapeuticscoreStrategic or Co-development PartnerCollaboration on TSRA-196 gene editing program for Alpha-1 Antitrypsin Disease. Part of Regeneron's gene editing expansion beyond the Intellia partnership.
• Hansoh Pharmaceutical GroupcoreStrategic or Co-development PartnerCollaboration on olatorepatide (HS-20094) for obesity — a GLP-1/GIP receptor agonist. 48-week Chinese study with 604 patients showed up to 19% weight loss; Regeneron plans to begin Phase 3 trials in 2025.
• Foundation for the National Institutes of Health (FNIH)coreStrategic or Co-development PartnerBiomarkers Consortium partner. Long-standing relationship for biomarker discovery and validation to support clinical development.
• Geisinger Health System (MyCode Community Health Initiative)coreStrategic or Co-development PartnerLong-standing RGC collaboration via the MyCode Community Health Initiative, which has enrolled 150,000+ volunteers who are notified if genetic changes associated with treatable conditions are found. The story of Barbara Barnes is a notable example of the program's impact.
• U.S. Government / TrumpRxcoreGTM or Marketing PartnerEngagement with the TrumpRx drug pricing platform — a U.S. government initiative listing more than 750 medications (including Regeneron products) to encourage cost-effective purchasing. Projected to save Americans over $500 billion over the next decade through most-favoured-nation agreements. Regeneron also participated in HHS/FDA National Priority Voucher program (Otarmeni approved under it).
• World Health Organization (WHO)coreStrategic or Co-development PartnerRegeneron's Ebola antibody (maftivimab) has been recommended by WHO for investigational use in response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of Congo. Regeneron has donated up to 500 doses of Ebola treatment to the WHO for exclusive use in low- and lower-middle-income countries.
• AppiancoreTechnology or IntegrationTechnology partnership for AI-driven enterprise process automation. Regeneron won an Appian 2026 North American Innovation Award at Appian World in Orlando, FL for embedding AI into core enterprise processes to achieve measurable business outcomes. Judged by IDC and Appian executives.
• Educational and nonprofit grant recipients (AMA, ACCME, OIG, PhRMA-adjacent organizations)peripheralOthersRegeneron operates four funding portals: Corporate funding application (patient advocacy groups, medical societies, STEM education, community-based organizations), Educational funding (CME, non-CME, academic fellowship, conference funding), Sponsorships & exhibits, and Third-party research requests. All interactions comply with AMA, ACCME, PhRMA, FDA, and OIG guidelines.

Scale indicators20 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Amgen: Large-cap biotech with a similarly broad biologics platform spanning antibodies, bispecifics (BiTE), and large-scale manufacturing. Amgen competes with Regeneron in ophthalmology indirectly and overlaps in oncology/immunology biologics manufacturing and pipeline breadth.
• Vertex Pharmaceuticals: Innovative mid-to-large biotech focused on serious diseases (CF, sickle cell, pain) with a comparable 'science-driven in-house discovery + collaboration' model. Vertex's Casgevy (CRISPR gene editing) directly parallels Regeneron's nexiguran ziclumeran gene-editing program in modality and rare-disease focus.
• Sanofi: Regeneron's largest collaborator (Dupixent, itepekimab, sarilumab) and a global immunology leader (Dupixent, Dupixent follow-ons). Sanofi is simultaneously partner and direct competitor in inflammation/immunology biologics.
• Genmab: Antibody-platform specialist (bispecifics, antibody-drug conjugates) with a similar in-house platform-plus-collaboration model (e.g., Darzalex with Janssen). Genmab directly parallels Regeneron's bispecific antibody pipeline.

Broad incumbents

• Gilead Sciences: Mature biotech with strong commercial franchises (HIV, oncology) and growing investment in cell therapy and antibody-drug conjugates. Gilead is a relevant comparable for Regeneron's commercial scale and oncology/hematology pipeline.
• Bristol-Myers Squibb: Major pharma with overlapping immunology and oncology biologics portfolios (PD-1 inhibitors, LAG-3 via Opdualag). BMS competes directly with Regeneron in immuno-oncology (nivolumab vs. cemiplimab) and immunology franchises.
• AbbVie: Immunology incumbent (Humira, Skyrizi, Rinvoq) competing head-to-head with Dupixent in atopic dermatitis, IBD, and other indications. Comparable R&D scale and immunology pipeline depth make AbbVie a key commercial and pipeline benchmark.

Emerging players

• Alnylam Pharmaceuticals: RNAi therapeutics pioneer and Regeneron's closest genetic-medicines modality partner (cemdisiran, ALN-HSD, ALN-APP, ALN-CFB, etc.). Comparable in modality focus and genetic-medicines pipeline depth.
• BioNTech: mRNA and immuno-oncology partner with Regeneron (PD-1 + FixVac combinations). BioNTech is a relevant comparable for next-gen oncology biologics and Regeneron's broader cell/vaccine collaborations.
• Moderna: mRNA-based biotech expanding from COVID-19 vaccines into oncology and rare disease. Comparable to Regeneron in pioneering a genetic-medicines platform, large-scale manufacturing footprint, and pipeline breadth outside its original franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/regeneron
• YouTubeyoutube.com/c/Regeneron
• Facebookfacebook.com/Regeneron
• LinkedInlinkedin.com/company/regeneron-pharmaceuticals
• Instagraminstagram.com/regeneron

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regeneron